Workflow
Chemours(CC)
icon
Search documents
Should Value Investors Buy Chemours (CC) Stock?
Zacks Investment Research· 2024-03-11 14:46
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, incl ...
Why Chemours Stock Soared Today
The Motley Fool· 2024-03-07 22:02
Shares of Chemours (CC 15.12%) rallied 16.8% today after the chemical company concluded an internal review that's loomed over the business for the past week, finding that that three top executives violated its code of ethics.Recall Chemours stock plummeted nearly 40% in a single day last Thursday after the company reported preliminary 2023 results and placed its CEO, CFO, and company controller on administrative leave pending the review. The review originally stemmed from an anonymous report made to Chemour ...
Chemours Provides Update on Internal Review
Businesswire· 2024-03-07 01:30
WILMINGTON, Del.--(BUSINESS WIRE)--As previously disclosed, the Audit Committee of the Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), with the assistance of independent outside counsel, has been overseeing an internal review. The review relates to an anonymous report made to the Chemours Ethics Hotline regarding the matters described below. A substantially complete report of the findings of the internal review was delivered to the full Board on March 5, 2024. Chair Daw ...
Renowned Litigation Firm Labaton Keller Sucharow LLP is Investigating The Chemours Company for Securities Violations and Encourages Investors to Contact the Firm
Businesswire· 2024-03-02 20:40
NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow, an award-winning shareholder rights firm, is investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”). Chemours is a global chemical manufacturer headquartered in Wilmington, Delaware. On February 13, 2024, Chemours announced that it would be delaying the release of its fourth quarter and full year 2023 financial results as the Company evaluates its internal controls over fi ...
Lost Money in the Chemours Company? Gibbs Law Group Investigates Potential Securities Law Violations
Businesswire· 2024-03-01 01:49
OAKLAND, Calif.--(BUSINESS WIRE)--Shares of The Chemours Company (“Chemours”) dropped over 31% on February 29, 2024, after the company announced that it has placed three top executives on administrative leave pending the completion of an internal review. The company also announced it is delaying the release of its financial results. Gibbs Law Group is investigating a potential Chemours Company Securities Class Action Lawsuit on behalf of shareholders who lost money in The Chemours Company (NYSE: CC). Wha ...
Berman Tabacco Announces Investigation of The Chemours Company (CC) for Potential Securities Law Violations
Newsfilter· 2024-02-29 18:05
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by The Chemours Company ("Chemours" or the "Company") (NYSE:CC). About the Investigation On February 29, 2024, in a Form 8-K filed with the U.S. Securities Exchange Commission, the Company stated that it had placed its President and Chief Executive Officer, Senior Vice President and Chief Financial Officer and Vice President, Controller and Principal Acco ...
Why Chemours Stock Crashed 37% This Morning
The Motley Fool· 2024-02-29 17:07
Shares of chemicals company Chemours (CC -33.08%) tumbled 37.3% through 11:10 a.m. ET on Thursday after announcing it will need to postpone the release of its Q4 and full-year financial results for 2023 -- and that it is replacing its CEO, its CFO, and its controller as well. In the meantime, as investors await its final and official results, management released preliminary estimates showing that sales probably fell 12% in 2023 and that the company flipped from a 2022 profit to a 2023 loss.Chemours manageme ...
Ademi LLP Investigates Claims of Securities Fraud against The Chemours Company
Prnewswire· 2024-02-29 15:54
MILWAUKEE, Feb. 29, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Chemours (NYSE: CC). The investigation results from inaccurate statements Chemours may have made regarding its accounting, business operations and prospects. Click here to learn more about the investigation: https://www.ademilaw.com/case/chemours-company or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses Chemours' determination of material w ...
Chemours Announces Management Actions and Delay of Form 10-K; Provides Preliminary Unaudited 2023 Year-End Results
Businesswire· 2024-02-29 03:14
WILMINGTON, Del.--(BUSINESS WIRE)--The Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) has appointed Denise Dignam as the Interim Chief Executive Officer and Matt Abbott as the Interim Chief Financial Officer (principal financial and accounting officer). Ms. Dignam joined Chemours in 2015 and has served as our President – Titanium Technologies since March 2023 and previously served as our President – Advanced Performance Materials from 2021 to 2023. She previously serv ...
Chemours Announces Changes to its Board of Directors
Businesswire· 2024-02-16 13:30
WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announces two upcoming changes to its Board of Directors. Director Sandra Phillips Rogers has announced her decision not to stand for reelection and will serve out the remainder of her current term. Pamela Fletcher will join the Chemours Board as a director, effective March ...